CR20110476A - Compuestos y usos de los mismos - Google Patents
Compuestos y usos de los mismosInfo
- Publication number
- CR20110476A CR20110476A CR20110476A CR20110476A CR20110476A CR 20110476 A CR20110476 A CR 20110476A CR 20110476 A CR20110476 A CR 20110476A CR 20110476 A CR20110476 A CR 20110476A CR 20110476 A CR20110476 A CR 20110476A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- same
- formulations
- salts
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen los compuestos y sales de los mismos, formulaciones de los mismos y usos de los mismos. En ciertos aspectos y realizaciones, los compuestos descritos o sales de los mismos, formulaciones, conjugados, derivados y formas de los mismos son activos sobre por lo menos una proteína quinasa Raf.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15939609P | 2009-03-11 | 2009-03-11 | |
US15939009P | 2009-03-11 | 2009-03-11 | |
US15939209P | 2009-03-11 | 2009-03-11 | |
US15940609P | 2009-03-11 | 2009-03-11 | |
US15940009P | 2009-03-11 | 2009-03-11 | |
US15939509P | 2009-03-11 | 2009-03-11 | |
US15940209P | 2009-03-11 | 2009-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110476A true CR20110476A (es) | 2012-01-04 |
Family
ID=42199540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110476A CR20110476A (es) | 2009-03-11 | 2011-09-06 | Compuestos y usos de los mismos |
Country Status (23)
Country | Link |
---|---|
US (1) | US8901301B2 (es) |
EP (1) | EP2406259A1 (es) |
JP (1) | JP2012520307A (es) |
KR (1) | KR101663339B1 (es) |
CN (1) | CN102421776A (es) |
AR (1) | AR075812A1 (es) |
AU (1) | AU2010224245B2 (es) |
BR (1) | BRPI1011515A2 (es) |
CA (1) | CA2755045A1 (es) |
CO (1) | CO6620074A2 (es) |
CR (1) | CR20110476A (es) |
EC (1) | ECSP11011313A (es) |
MA (1) | MA33181B1 (es) |
MX (1) | MX2011009489A (es) |
MY (1) | MY161861A (es) |
NI (1) | NI201100168A (es) |
NO (1) | NO20111241A1 (es) |
PE (1) | PE20120184A1 (es) |
RU (1) | RU2011141123A (es) |
SG (2) | SG174257A1 (es) |
TW (1) | TW201036973A (es) |
WO (1) | WO2010104945A1 (es) |
ZA (1) | ZA201106599B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
EP2170830B1 (en) | 2007-07-17 | 2014-10-15 | Plexxikon, Inc. | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP2012509342A (ja) | 2008-11-20 | 2012-04-19 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換ピロロ[2,3−b]−ピリジンおよび−ピラジン |
AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
PE20121327A1 (es) | 2009-11-06 | 2012-10-18 | Plexxikon Inc | Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello |
CA2781287C (en) | 2009-11-18 | 2018-07-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
MX2012007429A (es) * | 2009-12-23 | 2012-07-23 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasa e indicaciones de la misma. |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
JP2013526570A (ja) | 2010-05-14 | 2013-06-24 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 縮合二環式キナーゼ阻害剤 |
AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
US8771687B2 (en) | 2010-12-02 | 2014-07-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods for treating a tumor using an antibody that specifically binds GRP94 |
PL2672967T3 (pl) * | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Związki i sposoby modulacji kinaz i wskazania ku temu |
WO2012149547A1 (en) * | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
EP2709622A4 (en) | 2011-05-17 | 2015-03-04 | Plexxikon Inc | CINEMA MODULATION AND INDICATIONS THEREFOR |
US9988687B2 (en) * | 2011-09-20 | 2018-06-05 | The George Washington Univeristy | Companion diagnostics for cancer and screening methods to identify companion diagnostics for cancer based on splicing variants |
EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
TWI601725B (zh) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | 取代的氮雜吲哚化合物及其鹽、組合物和用途 |
AU2013312477B2 (en) | 2012-09-06 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2014081760A1 (en) | 2012-11-20 | 2014-05-30 | Duke University | Methods of treating hemoglobinopathies |
AR094263A1 (es) | 2012-12-21 | 2015-07-22 | Plexxikon Inc | Compuestos moduladores selectivos de proteinquinasas |
NZ630875A (en) | 2013-03-15 | 2017-12-22 | Plexxikon Inc | Heterocyclic compounds and uses thereof |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物 |
BR112015028845A2 (pt) | 2013-05-30 | 2017-07-25 | Plexxikon Inc | compostos para a modulação da quinase e indicações da mesma |
EP3094736A4 (en) | 2014-01-14 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2016044067A1 (en) | 2014-09-15 | 2016-03-24 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
RS60731B1 (sr) | 2015-05-06 | 2020-09-30 | Plexxikon Inc | Čvrsti oblici jedinjenja koje modulira kinaze |
KR102637844B1 (ko) | 2015-05-06 | 2024-02-19 | 다이이치 산쿄 인코포레이티드 | 키나아제를 조절하는 1h-피롤로[2,3b]피리딘 유도체의 합성 |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
MY195977A (en) | 2015-09-21 | 2023-02-27 | Plexxikon Inc | Heterocyclic Compounds and uses Thereof |
CA3007462C (en) | 2015-12-07 | 2023-10-24 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AU2017232610B2 (en) | 2016-03-16 | 2021-07-22 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Cdk8調節およびその適応症のための化合物および方法 |
CA3049926A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
WO2019023198A1 (en) | 2017-07-25 | 2019-01-31 | Plexxikon Inc. | FORMULATION OF A COMPOUND MODULATING KINASES |
CN111194318B (zh) | 2017-10-13 | 2023-06-09 | Opna生物公司 | 用于调节激酶的化合物固体形式 |
AU2018354423A1 (en) | 2017-10-27 | 2020-05-14 | Plexxikon Inc. | Formulations of a compound modulating kinases |
SG11202007143UA (en) | 2018-01-31 | 2020-08-28 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
WO2019243315A1 (en) | 2018-06-21 | 2019-12-26 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2020016243A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
MX2021012278A (es) | 2019-04-09 | 2021-11-12 | Plexxikon Inc | Azinas condensadas para la modulacion de ep300 o cbp e indicaciones de estos. |
AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
AU2021327375A1 (en) | 2020-08-21 | 2023-03-16 | Opna Bio SA | Combinational drug anticancer therapies |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102516417B (zh) | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
AU2006261993B2 (en) * | 2005-06-22 | 2011-11-17 | Plexxikon, Inc. | Pyrrolo (2, 3-B) pyridine derivatives as protein kinase inhibitors |
PE20081581A1 (es) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
-
2010
- 2010-03-10 EP EP10708681A patent/EP2406259A1/en not_active Withdrawn
- 2010-03-10 CA CA2755045A patent/CA2755045A1/en not_active Abandoned
- 2010-03-10 WO PCT/US2010/026816 patent/WO2010104945A1/en active Application Filing
- 2010-03-10 PE PE2011001620A patent/PE20120184A1/es not_active Application Discontinuation
- 2010-03-10 CN CN2010800206771A patent/CN102421776A/zh active Pending
- 2010-03-10 SG SG2011063914A patent/SG174257A1/en unknown
- 2010-03-10 MA MA34228A patent/MA33181B1/fr unknown
- 2010-03-10 TW TW099106990A patent/TW201036973A/zh unknown
- 2010-03-10 AU AU2010224245A patent/AU2010224245B2/en active Active
- 2010-03-10 MX MX2011009489A patent/MX2011009489A/es not_active Application Discontinuation
- 2010-03-10 SG SG10201402977WA patent/SG10201402977WA/en unknown
- 2010-03-10 KR KR1020117023712A patent/KR101663339B1/ko active IP Right Grant
- 2010-03-10 MY MYPI2011004233A patent/MY161861A/en unknown
- 2010-03-10 AR ARP100100731A patent/AR075812A1/es unknown
- 2010-03-10 US US12/721,496 patent/US8901301B2/en active Active
- 2010-03-10 RU RU2011141123/04A patent/RU2011141123A/ru unknown
- 2010-03-10 BR BRPI1011515A patent/BRPI1011515A2/pt not_active Application Discontinuation
- 2010-03-10 JP JP2011554147A patent/JP2012520307A/ja not_active Withdrawn
-
2011
- 2011-08-09 EC EC2011011313A patent/ECSP11011313A/es unknown
- 2011-09-06 CR CR20110476A patent/CR20110476A/es unknown
- 2011-09-08 ZA ZA2011/06599A patent/ZA201106599B/en unknown
- 2011-09-09 NI NI201100168A patent/NI201100168A/es unknown
- 2011-09-12 CO CO11117856A patent/CO6620074A2/es not_active Application Discontinuation
- 2011-09-13 NO NO20111241A patent/NO20111241A1/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA201106599B (en) | 2014-02-26 |
PE20120184A1 (es) | 2012-03-28 |
TW201036973A (en) | 2010-10-16 |
SG10201402977WA (en) | 2014-09-26 |
MY161861A (en) | 2017-05-15 |
US20100286178A1 (en) | 2010-11-11 |
AU2010224245B2 (en) | 2016-07-21 |
CA2755045A1 (en) | 2010-09-16 |
CN102421776A (zh) | 2012-04-18 |
NO20111241A1 (no) | 2011-09-28 |
AR075812A1 (es) | 2011-04-27 |
US8901301B2 (en) | 2014-12-02 |
BRPI1011515A2 (pt) | 2016-03-29 |
NI201100168A (es) | 2012-01-11 |
RU2011141123A (ru) | 2013-04-20 |
KR101663339B1 (ko) | 2016-10-06 |
WO2010104945A1 (en) | 2010-09-16 |
EP2406259A1 (en) | 2012-01-18 |
ECSP11011313A (es) | 2011-10-31 |
JP2012520307A (ja) | 2012-09-06 |
KR20110125670A (ko) | 2011-11-21 |
MA33181B1 (fr) | 2012-04-02 |
CO6620074A2 (es) | 2013-02-15 |
MX2011009489A (es) | 2011-10-11 |
AU2010224245A1 (en) | 2011-09-29 |
SG174257A1 (en) | 2011-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110476A (es) | Compuestos y usos de los mismos | |
CR20120536A (es) | Compuestos y métodos para la modulación de quinasa e indicaciones de la misma | |
CR20110562A (es) | Compuestos y métodos para la modulación de las quinasas e indicaciones de los mismos | |
CR20120221A (es) | Compuestos y métodos para la modulación de cinasas, e indicaciones para ello | |
BRPI0718182A2 (pt) | Oligorribonucleotídeos e seus usos. | |
UY31829A (es) | Compuestos y métodos para modulación de cinasas, e indicaciones para ello | |
BRPI0814267A2 (pt) | Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico. | |
BRPI0816075A2 (pt) | 2-(fenil substituído)-6-amino-5-alcóxi, tioalcóxi e aminoalquil-4-pirimidinacarboxilatos e seus usos como herbicidas | |
BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
CY1122168T1 (el) | Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης | |
BRPI0915897A2 (pt) | compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos | |
BRPI0924183A2 (pt) | inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso | |
BRPI0808098A2 (pt) | 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso | |
BRPI1014034A2 (pt) | formulação e seu uso, composição, solução injetável e kit. | |
SMP200800041B (it) | Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori | |
BRPI1016150A2 (pt) | compostos heterocíclicos e seus usos. | |
BRPI0809583A2 (pt) | polipeptídeos fgf-21 modificados e seus usos | |
BRPI0818690A2 (pt) | Derivados de quinazolinediona, sua preparação e seus usos terapêuticos. | |
BRPI0922435A2 (pt) | "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso." | |
ECSP099684A (es) | Aril pirrolidinas insecticidas | |
CO6511251A2 (es) | Compuestos quimicos | |
CL2008003406A1 (es) | Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih. | |
UY32659A (es) | Pirazinilpirazoles | |
BRPI0813455A2 (pt) | Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado. | |
BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. |